Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~Exclusion Criteria:~* Age \< 18 years~* Pregnancy or breast feeding or woman of childbearing potential not using~* adequate contraception.~* Participation in a clinical trial of an investigational medicinal product within 30 days~* Consent declined Aspirin or non steroidal anti-inflammatory (NSAID) use in the past 4 weeks~* History of asthma~* Known aspirin or NSAID hypersensitivity~* History of peptic ulcer disease~* Platelet count \< 150 x 106/ml~* Aspirin resistance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Aspirin 75mg (Type: ACTIVE_COMPARATOR): Aspirin 75mg once daily for 7 days. Administered by mouth.
- Aspirin 1200mg (Type: ACTIVE_COMPARATOR): Asprin 600mg twice daily for 7 days. Administered by mouth.
- Lactose powder (Type: PLACEBO_COMPARATOR): Placebo for 7 days. Administered by mouth.

Based on this trial design, predict the completion outcome and termination type (if applicable).